Shenzhen Authorities Hold Collective Meeting with Aesthetic Clinics; Xingyue Bio's Silk Fibroin Hydrogel Gains Approval; Maijie Life Sciences Completes Tens of Millions RMB Series A+ Round

On January 21, Mr. Long Wen, Vice General Manager of SiruiMei Biotech, a wholly-owned subsidiary of Zhejiang Xingyue Biotechnology Co., Ltd., announced significant news: After relentless efforts and innovative exploration, the "Silk Fibroin Medical Gel (Zhejiang Medical Device Registration Approval No. 20252141063)" independently developed by SiruiMei Biotech has successfully received approval from the Zhejiang Provincial Drug Administration.

On January 17, Shenzhen Medgen Life Sciences Co., Ltd. announced that it had completed a multi-million yuan A+ round of financing exclusively invested by YuanSheng Ventures. This round of financing is the company's second in nearly two months, with the cumulative amount of the first two rounds of financing reaching nearly 100 million yuan. This round of financing will further replenish the company’s working capital and be used for the clinical advancement of the company’s current medical aesthetics products, as well as the sales promotion of orthopedic innovative products after their market launch.(Source:Interface News)

Reporters learned that on January 21, 2025, the Shenzhen Market Supervision Administration and the Shenzhen Medical Beauty Industry Association held a "Collective Meeting on the Compliance of Medical Devices in Medical Aesthetic Institutions." According to previously circulated notices within the industry, the meeting covered products such as hydroxyapatite, aiming to ensure the quality and safety of medical device products. The attendee list included several well-known medical aesthetic institutions and upstream medical device manufacturing enterprises.(Source:21st Century Business Herald)